1 active not recruiting, 1 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Elafibranor 120 mg: new trials by email Literature Review of Elafibranor 120 mg trials Research Report on Elafibranor 120 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg - Primary Sclerosing Cholangitis | Phase 2 | Active not recruiting | Ipsen | 68 | 2022-12-29 | 2026-10-23 |
| Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid Elafibranor 80 mg, Elafibranor 120 mg, Placebo - Primary Biliary Cholangitis (PBC) | Phase 2 | Completed | Genfit | 45 | 2017-04-05 | 2019-09-24 |
Cholangitis, Sclerosing (1) · Liver Cirrhosis, Biliary (1)
Germany (2) · Spain (2) · United Kingdom (2) · United States (2) · Canada (1) · France (1) · Italy (1) · Portugal (1)
2016 (1)